Life science industry commits to share vital antibiotics resistance surveillance data and call for greater collaboration

“We need to better understand what we are dealing with. Know your enemy are the watch words in this case. Systematic and widespread surveillance is important to understand where resistant pathogens are emerging. We support the World Health Organization (WHO) Global Antimicrobial Resistance Surveillance System (GLASS) to enlist countries in collecting data. Today, companies are increasingly sharing the data they have been collecting, and as a result we can use the information to assess the scale of the problem, pin-point places where resistant pathogens exist, and make more informed decisions on the ground when assessing treatment solutions”.

Thomas Cueni, Chair of the AMR Industry Alliance

29th January 2018, Geneva - The AMR Industry Alliance of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations, formed to drive and measure industry progress to curb antimicrobial resistance are committed to supporting measures that ensure appropriate use of antibiotics. Many Alliance companies are collecting surveillance data to better understand incidence rates of resistance to various antibiotics and are currently, or planning to, openly share their surveillance data externally.

Surveillance data is essential to public health bodies and healthcare professionals to help make better informed decisions to treat patients who need antibiotics most effectively. In the Industry Roadmap for Progress on Combating AMR, Alliance members commit to “continue to share the surveillance data we generate with public health bodies and healthcare professionals, and work with them to improve understanding of resistance trends, inform appropriate antibiotic and vaccine use and, over time, thereby help increase surveillance capabilities globally”1.

In tracking companies’ commitments, the AMR Industry Alliance’s recent progress report found that:

- Nearly 90% of responding companies are planning to, currently collecting or support the collection of surveillance data, and 60% are currently, or planning to, openly share their surveillance data externally. Companies share surveillance data by many different routes, from scientific publications to web- and app-based systems.
- These companies collect a range of data including: pathogen incidence, pathogen resistance profiles, product consumption/use, sales of product(s) to treatment sites.
- Collectively, these surveillance systems collect data from countries in all regions of the world. Some surveillance programs have been running for more than 16 years, which allows researchers to identify trends in the development of resistance, and can cover more than 60 countries.

The Alliance supports the World Health Organization (WHO) Global Antimicrobial Resistance Surveillance System (GLASS) and calls for more collaboration and analysis across the datasets. Many Alliance member companies are exploring opportunities to make the surveillance data they collect more accessible to healthcare professionals and public health bodies. The Alliance is open to collaborating with the WHO, member states and other stakeholders to strengthen surveillance capabilities, in particular in low resource settings.

Examples of industry’s surveillance activity include: the Survey of Antibiotic Resistance, GSK; Study for Monitoring Antimicrobial Resistance Trends, Merck & Co., Inc; Antimicrobial Testing Leadership and Surveillance Program, Pfizer, Inc.; Global Point Prevalence Survey, a collaboration between Antwerp University & bioMérieux. For more information, please see page 51 of the Progress Report, more case studies are available here).

---

1 The full Roadmap is available here.
**Context**

On 29th January, the WHO, Global Antimicrobial Resistance Surveillance System (GLASS) will launch its first report at the **Prince Mahidol Award Conference 2018** in Bangkok, Thailand, from 29 January – 3 February 2018. GLASS is the first global system to collect official national data about antimicrobial resistance in bacterial pathogens that cause common infections in humans. Since its launch, 51 countries have enrolled in the system and more countries are in the process of joining.

**About the AMR Industry Alliance**

The AMR Industry Alliance is a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. The AMR Industry Alliance ensures that signatories collectively deliver on the specific commitments made in the **Industry Declaration** on AMR and the **Roadmap** and measures progress made in the fight against antimicrobial resistance.

[www.amrindustryalliance.org](http://www.amrindustryalliance.org)

- Full Progress report: [https://www.amrindustryalliance.org/progress-report/](https://www.amrindustryalliance.org/progress-report/)
- Case studies: [https://www.amrindustryalliance.org/in-action](https://www.amrindustryalliance.org/in-action)

**Annex – AMR Industry Alliance progress report information on appropriate use and surveillance data**

---

**Figure 14: Proportion of responding company appropriate use strategies, policies or plans addressing these aspects of appropriate use (total: 16).**
The type of data collected by companies varies.

**FIGURE 15:** PROPORTION OF COMPANIES, BY SECTOR, CURRENTLY COLLECTING OR SUPPORTING THE COLLECTION OF SURVEILLANCE DATA (TOTAL: 35).

**FIGURE 16:** TYPE OF SURVEILLANCE DATA COLLECTED BY RESPONDING COMPANIES (TOTAL: 21).
Statement
29/01/2018

Press contact
Morgane De Pol
m.depol@amrindustryalliance.org
+41 22 338 32 20